At a glance
- Originator Daiichi Fine Chemical
- Class Antithrombotics
- Mechanism of Action Cyclooxygenase inhibitors; Platelet aggregation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Thrombosis
Most Recent Events
- 17 Jan 2001 Discontinued-Preclinical for Thrombosis in Japan (Unknown route)
- 14 Mar 2000 No-Development-Reported for Thrombosis in Japan (Unknown route)
- 25 Feb 1997 Preclinical development for Thrombosis in Japan (Unknown route)